Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.0)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 1, January-February, p. 127–134

Publication type: review article

Language: Polish

Rola LBP w transdukcji sygnału indukowanego LPS i w modulacji odpowiedzi układu immunologicznego

The Role of LBP in Transduction of Signal Induced by LPS and in Modulation of Immune System Response

Magdalena Mierzchała1,, Małgorzata Lipińska−Gediga1,, Grażyna Durek1,

1 Katedra i Klinika Anestezjologii i Intensywnej Terapii AM we Wrocławiu

Streszczenie

Każdy czynnik infekcyjny i nieinfekcyjny (zabieg operacyjny, uraz) prowadzi do aktywacji układu immunologicznego, co powoduje uwalnianie do krążenia mediatorów zapalnych, takich jak: TNF−α (tumor necrosis factor alpha), IL−6 (interleukin−6), PCT (procalcitonin) oraz białek ostrej fazy, np. LBP (lipopolysaccharide−binding protein). Elementami bakteryjnymi odpowiedzialnymi za indukcję mechanizmów obronnych organizmu są: lipopolisacharyd – składnik ściany komórkowej bakterii Gram−ujemnych oraz peptydoglikan i kwas tejchojowy (składniki ściany komórkowej bakterii Gram−dodatnich. Wszystkie te składniki reagują z białkami i receptorami, tj. z osoczowymi lipoproteinami, LBP, receptorami CD14 i Toll−like. Według aktualnych poglądów LBP jest białkiem ostrej fazy modulującym odpowiedź immunologiczną przez aktywację komórek fagocytujących i komórek prezentujących antygen. Obecnie rozważa się możliwość stosowania oznaczeń stężenia LBP w surowicy jako wskaźnika diagnostycznego i monitorującego skuteczność terapii u pacjentów z rozpoznaniem rozległej infekcji na oddziałach intensywnej terapii.

Abstract

Every factor infectious and noninfectious (surgery, trauma) contribute to immune system activation, which results in releasing of inflammatory mediators: TNF−α (tumor necrosis factor alpha), IL−6 (interleukin−6), PCT (procalcitonin) and acute−phase proteins, i.e. LBP (lipopolysaccharide−binding protein), into circulation. The bacterial factors, are being responsible for host defensive mechanisms induction, are lipopolysaccharide – Gram(–) bacteria cell wall component and peptidoglycan and teichoic acid – Gram(+) bacteria cell wall component. Each of these factors interacts with proteins and receptors, i.e.: with plasma lipoproteins, LBP and CD14 and Toll−like receptors. According to the current opinions LBP is the acute phase protein, which modulates immunological response by phagocytes and presenting antigen cells activation. It is considered that level LBP measurements can be used as diagnostic parameter monitoring efficacy of intensive care patients therapy.

Słowa kluczowe

endotoksyna, białko wiążące lipopolisacharyd, receptor CD14, receptory Toll−like

Key words

endotoxin, lipopolysaccharide−binding protein, receptor CD14, Toll−like receptors

References (51)

  1. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16, 379–414.
  2. Fischer W: Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med Microbiol Immunol 1994, 183, 61–76.
  3. Fischer W, Koch HU: Alanyl lipoteichoic acid of Staphylococcus aureus: functional and dynamic aspects. Biochem Soc Trans 1985, 13, 984–986.
  4. Rose RK, Hogg SD: Competitive binding of calcium and magnesium to streptococcal lipoteichoic acid. Biochim Biophys Acta 1995, 1245, 94–98.
  5. Navarre WW, Schneewind O: Surface proteins of gram−positive bacteria and mechanism of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 1999, 63, 174–229.
  6. Giesbrecht P, Kersten T, Maidhof H, Wecke J: Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicilin. Microbiol Mol Biol Rev 1998, 62, 1371–1414.
  7. Frank MM, Fries LS: The role of complement in inflammation and phagocytosis. Immunol Today 1991, 12, 322–331.
  8. Kirschning CJ, Unbehaun A, Fiedler G, Hallatschek W, Lamping N, Pfeil D, Schumann RR: The Transcriptional Activation Pattern of Lipopolysaccharide Binding Protein (LBP) Involving Transcription Factors AP−1 and C/EBPβ. Immunobiol 1997, 198, 124–135.
  9. Schumann RR, Leong SR, Flaggs GW, Gray GW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990, 249, 1429–1431.
  10. Schumann RR, Zweigner J: A novel acutephase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 1999, 37, 271–274.
  11. Triantafilou M, Triantafilou K: Lipopolysaccharide recognition: CD14, TRLs and the LPS−activation cluster. Trends Immunol 2002, 23, 301–304.
  12. Ulevitch RJ, Tobias PS: Recognition of gram−negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999, 11, 19–22.
  13. Ramadori G, Meyer zum Buschenfelde KH, Tobias P S, Mathison JC, Ulevitch RJ: Biosynthesis of lipopolysaccharide – binding protein in rabbit hepatocytes. Pathobiology 1990, 58, 89–94.
  14. Vreugdenhil AC, Dentener AM, Snoek AM, Greve JV, Buurman WA: Lipopolysaccharide – binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999, 163, 2792–2798.
  15. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR: High concentrations of lipopolysaccharide−binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001, 13, 3800–3808.
  16. Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR: Organization of the human cholesteryl ester transfer protein gene. Biochemistry 1990, 29, 1372–1376.
  17. Kirschning CJ, Au−Young J, Lamping N, Reuter D, Pfeil D, Seilhamer J, Schumann RR: Similar organization of the lipopolysaccharide−binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid−binding proteins. Genomics 1997, 46, 416–425.
  18. Tobias PS, Mathison JC, Ulevitch RJ: A family of lipopolysaccharide – binding proteins involve in responses to gram−negative sepsis. J Biol Chem 1988, 263, 13479–13481.
  19. Tobias PS, Mathison JC, Mintz D, Lee JD, Kravchenko V, Kato K, Pugin J, Ulevitch RJ: Participation of lipopolisaccharide binding protein in lipopolisaccharide−dependent macrophage activation. Am. J Respir. Cell Mol Biol 1992, 7 239–245.
  20. Kirschning CJ, Unbehaun A, Lamping N, Pfeil D, Herrmann F, Schumann RR: Control of transcriptional activation of the lipopolysaccharide−binding protein (LBP) gene by proinflammatory cytokines. Cytokines Cell Mol Ther 1997, 3, 59–62.
  21. Schumann RR, Latz E: Lipopolysaccharide−binding protein. Chem Immunol 2000, 74, 42–60.
  22. Tall AR, Forester LR, Bongivanni GL: Facilitation of phosphatidylcholine transfer into high density lipoproteins by an apolipoprotein in the 1.20–1.26 g/ml fraction of plasma. J Lipid Res, 1983, 24, 277–289.
  23. Ulevitch RJ, Johnston AR: The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Investig 1978, 62, 1313–1324.
  24. Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide−high density lipoprotein complex formed in rabbit plasma. J Clin Investig 1981, 67, 827–837.
  25. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA: The role of lipoproteins and receptor−mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986, 83, 2704–2708.
  26. Netea MG, Demacker PN, Kullberg BJ, Jacobs LE, Verver−Jansen T, Boerman OC, Stalenhoef AF, Van der Meer JW: Bacterial lipopolysaccharide binds and stimulates cytokine−producing cells before neutralization by endogenous lipoproteins can occur. Cytokine 1998, 10, 766–772.
  27. Lamping N, Dettmer R, Schroeder NWJ, Pfeil D, Hallatscheck W, Burger R, Schumann RR: LPS−binding protein protects mice from septic shock caused by LPS or Gram−negative bacteria. J Clin Investig 1998, 101, 2065–2071.
  28. White ML, Ma JK, Mendoza NT, Dedrick RL, Carroll SF: Differential acute phase response between subjects with inflammatory, infectious and non−infectious disease. Abstracts of the 35th ICAAC 1995, 77.
  29. Froon AHM, Dentener MA, Willem J, Greve M, Ramsay G, Buurman WA: Lipopolysaccharide toxicity−regulating proteins in bacteriemia. J Infect Dis 1995, 171, 1250–1257.
  30. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS−binding protein in patients with severe sepsis and septic shock. J Infect. Dis 1999, 180, 1584–1589.
  31. Blairon L, Wittebole X, Laterre PF: Lipopolysaccharide−binding protein serum levels in patients with severe sepsis due to Gram−positive and fungal infections. J Infect Dis 2003, 187, 287–291.
  32. Kaden J, Zwerenz P, Lambrecht HG, Dostatni R: Lipopolysaccharide−binding protein as a new and reliable infection marker after kidney transplantation. Transpl Int 2002, 15, 163–172.
  33. Orlikowsky T, Schumacher C, Deperschmidt N, Henkel C, Niethammer D, Goetz R: Lipopolysaccharid (LPS)−bindendes Protein (LBP) im Plasma von gesunden Neugeborenen und Neugeborenen mit neonataler bakterieller Infektion. Z Geburtshilfe Neonatol 2001, 205 (Suppl. 1): S26–S27.
  34. Yu B, Wright SD: Catalytic properties of lipopolysaccharide (LPS) binding protein (LBP): Transfer of LPS to soluble CD14. J Biol Chem 1996, 271, 4100–4105.
  35. Gutsmann T, Müller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U: Dual role of lipopolysaccharide (LPS)−binding protein in neutralization of LPS and enhancement of LPS−induced activation of mononuclear cells. Infect Immun 2001, 69, 6942–6950.
  36. Pruchal M, Herold I, Zazula R, Dubska L, Dostal M, Hildebrand T, Hyanek J: Significance of lipopolysaccharide−binding protein (an acute phase protein) in monitoring critically ill patients. Critical Care 2003, 7, R154–R159.
  37. Tobias PS, Soldau K, Ulevitch RJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide−binding protein. J Biol Chem 1989, 264, 10867–10871.
  38. Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide−binding acute phase reactant from rabbit serum. J Exp Med 1986, 164, 777–793.
  39. Morrison DC, Ryan LJ: Endotoxins and disease mechanisms. Ann Rev Med 1987, 38, 417–432.
  40. Rietschel ET, Brade H, Brade L, Brandenburg K, Schade U, Seydel U, Zahringer U, Galanos C, Luderitz O, Westphal O: Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. Prog Clin Biol Res 1987, 231, 25–53.
  41. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249, 1431–1433.
  42. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS: Toll−like receptor 4, but not Toll−like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000, 165, 5780–5787.
  43. Berner R, Fürll B, Stelter F, Dröse J, Müller H−P, Schütt C: Elevated Levels of Lipopolysaccharide Binding Protein and Soluble CD14 in Plasma in Neonatal Early−Onset Sepsis. Clin Diag Lab Immun 2002, 9, 440–445.
  44. Wright SD: CD14 and immune response to lipopolysaccharide. Science (Wash. DC), 1991, 252, 1321–1322.
  45. Schröder NW, Heine H, Alexander C, Manukyan M, Eckert J, Hamann L, Göbel UB, Schumann RR: Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immun 2004, 173, 2683–2691.
  46. Weber JR, Freyer D, Alexander C, Schroder NWJ, Reiss A, Kuster C, Pfeil D, Tuomanen E, Schumann RR: Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 2003, 19, 269–279.
  47. Horwitz AH, Williams RE, Nowakowski G: Human lipopolysaccharide−binding protein potentiates bactericidal activity of human bactericidal/permeability−increasing protein. Infect Immun 1995, 63, 522–527.
  48. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA: Lipopolysaccharide (LPS) binding protein opsonizes LPS−bearing particles for recognition by novel receptor on macrophages. J Exp Med 1989, 170, 1231–1241.
  49. White ML, Ma JK, Birr CA, Trown PW, Carroll SF: Measurement of bactericidal/permeability−increasing protein in human body fluids by sandwich ELISA. J Immunol Methods 1994, 167, 227–236.
  50. Martin TR, Mathison JC, Tobias PS, Leturcq DJ, Moriarty AM, Maunder RJ, Ulevitch RJ: Lipopolysaccharide binding protein enhances the reponsiveness of alveolar macrophages to bacterial lipopolysaccharide. J Clin Invest 1992, 90, 2209–2219.
  51. Pavcnik−Arnol M, Hojker S, Derganc M: Lipopolysaccharide−binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin−6 and C−reactive protein. Intensive Care Med 2004, 30, 1454–1460.
© Wroclaw Medical University